Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib vs Best Available Therapy in Chinese Patients With CML-CP
NCT04795427Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Dec 2021; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04795427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795427.